{
  "id": "5e2906948b3851296d00000a",
  "type": "yesno",
  "question": "Is Niraparib effective for ovarian cancer?",
  "ideal_answer": "Yes. Niraparib is an oral poly(ADP ribose) polymerase (PARP) inhibitor that is approved by the United States Food and Drug Administration and the European Medicines Agency for the maintenance treatment of women with recurrent ovarian cancer who are in complete or partial response to platinum-based chemotherapy.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29251678",
    "http://www.ncbi.nlm.nih.gov/pubmed/28474297",
    "http://www.ncbi.nlm.nih.gov/pubmed/29081841",
    "http://www.ncbi.nlm.nih.gov/pubmed/29327913",
    "http://www.ncbi.nlm.nih.gov/pubmed/30073633",
    "http://www.ncbi.nlm.nih.gov/pubmed/29322231",
    "http://www.ncbi.nlm.nih.gov/pubmed/29397193",
    "http://www.ncbi.nlm.nih.gov/pubmed/27810860",
    "http://www.ncbi.nlm.nih.gov/pubmed/29911447",
    "http://www.ncbi.nlm.nih.gov/pubmed/28994564",
    "http://www.ncbi.nlm.nih.gov/pubmed/27717299",
    "http://www.ncbi.nlm.nih.gov/pubmed/30293481",
    "http://www.ncbi.nlm.nih.gov/pubmed/28299955"
  ],
  "snippets": [
    {
      "text": "Niraparib and olaparib have been approved by the US FDA for maintenance therapy after partial or complete remission in recurrent ovarian cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28994564",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE OF REVIEW: The recent United States Food and Drug Administration approvals of niraparib and olaparib as maintenance monotherapy for platinum-sensitive, high-grade ovarian cancers independent of BRCA status reflect a willingness to seek indications for poly-ADP-ribose polymerase (PARP) inhibitors beyond cancers with deleterious breast cancer 1 and breast cancer 2 mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29251678",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Niraparib is a highly selective inhibitor of PARP-1 and PARP-2 approved in the United States for maintenance treatment of adult patients with recurrent ovarian cancer in complete or partial response to platinum-based chemotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29322231",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Indeed, three PARP1 inhibitors (Olaparib, Rucaparib, and Niraparib) have recently been approved by the Food and Drug Administration for the treatment of ovarian cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29327913",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Niraparib is an oral poly(ADP ribose) polymerase (PARP) inhibitor that is currently approved by the United States Food and Drug Administration (US FDA) as well as recently approved by the European Medicines Agency (EMA) for the maintenance treatment of women with recurrent ovarian cancer who are in complete or partial response to platinum-based chemotherapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29397193",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Niraparib is a poly adenosine diphosphate ribose polymerase inhibitor that has shown to be clinically effective as maintenance therapy in patients with platinum sensitive, recurrent ovarian cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30293481",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27717299",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Niraparib for the treatment of ovarian cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29911447",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND\n\nNiraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27717299",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Niraparib Slows Ovarian Cancer Progression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27810860",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Niraparib for the treatment of ovarian cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28299955",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "INTRODUCTION\n\nNiraparib, an orally available selective inhibitor of poly(adenosine diphosphate-ribose) polymerase (PARP), is the first PARP inhibitor approved for use in patients with ovarian cancer who do not harbor a germ-line or somatic mutation in the breast cancer gene (BRCA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29911447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The role of niraparib as maintenance following frontline platinum-based chemotherapy as well as in the treatment of recurrent high-grade serous ovarian cancer is an active area of investigation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29911447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Niraparib in ovarian cancer: results to date and clinical potential.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29081841",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Niraparib , an orally available selective inhibitor of poly(adenosine diphosphate-ribose ) polymerase ( PARP) , is the first PARP inhibitor approved for use in patients with ovarian cancer who do not harbor a germ-line or somatic mutation in the breast cancer gene ( BRCA) . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29911447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results from a phase III trial indicate that maintenance therapy with the PARP inhibitor niraparib is more effective than placebo in slowing the progression of recurrent platinum-sensitive ovarian cancer . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27810860",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Niraparib (Zejula\u00ae), a poly (ADP-ribose) polymerase (PARP) inhibitor, is approved for the maintenance treatment of recurrent, epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to platinum-based chemotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30073633",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Niraparib, an orally available selective inhibitor of poly(adenosine diphosphate-ribose) polymerase (PARP), is the first PARP inhibitor approved for use in patients with ovarian cancer who do not harbor a germ-line or somatic mutation in the breast cancer gene (BRCA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29911447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Current evidence suggests that niraparib is an effective new option with a manageable tolerability profile for the maintenance treatment of recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults, with or without BRCA1/2 mutation or HRD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30073633",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Oral niraparib, a highly-selective, potent poly(ADP-ribose) polymerase (PARP)-1 and PARP-2 inhibitor, is approved in the USA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28474297",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of niraparib leading to its first global approval for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28474297",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Niraparib (Zejula ), a poly (ADP-ribose) polymerase (PARP) inhibitor, is approved for the maintenance treatment of recurrent, epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to platinum-based chemotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30073633",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Niraparib, an orally available selective inhibitor of poly(adenosine diphosphate-ribose) polymerase (PARP), is the first PARP inhibitor approved for use in patients with ovarian cancer who do not harbor a germ-line or somatic mutation in the breast cancer gene (BRCA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29911447",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}